[Correspondence] “Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy?

We read with great interest the results of the NEMO trial by Reinhard Dummer and colleagues,1 a phase 3 study of binimetinib versus dacarbazine in advanced melanoma, which offers a long-awaited therapeutic alternative for patients with NRAS-mutant melanoma.

http://ift.tt/2szvyPU